Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Becoming a Life Sciences Lawyer – The View From Goodwin (Chambers Associate)

Related Content

Register Today: Webinar Series: An Overview of the Biosimilars Market in China, and Comparison with the US Market

USPTO Issues Revised Inventorship Guidance for AI-Assisted Inventions: Key Takeaways for AI/ML Innovators

European Commission Approves Alvotech’s and Teva’s Denosumab Biosimilars

Formycon Announces New Dupilumab Biosimilar Candidate

Sandoz Launches Natalizumab Biosimilar

Sandoz and EirGenix Enter Licensing Agreement to Commercialize Proposed Pertuzumab Biosimilar

Amgen Files BPCIA Complaint Against Alkem Related to Denosumab Biosimilar

FDA Approves Accord BioPharma’s Denosumab Biosimilars

State Drug Price Transparency Laws and Prescription Drug Affordability Boards – 2025 Year-End Review Webinar

Goodwin Guides Freenome in Over $200 Million Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

Goodwin Earns Top Rankings in League Tables for Q3 2025

Goodwin Advises Q32 Bio in Sale of Complement Inhibitor ADX-097 for Up to $592 Million

Goodwin Advises Moderna with Its $1.5 Billion Five-Year Credit Facility from Ares Management

Goodwin Advises AI Proteins on $41.5 Million Series A Financing

Goodwin Advises Esperion on $75 Million Underwritten Public Offering

Goodwin Advises Halda Therapeutics on $3.05 Billion Acquisition Agreement with Johnson & Johnson

Life Sciences

Intellectual Property